Experimental stent graft for aortic tear tested in single patient
NCT ID NCT03322033
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a stent graft device to repair a tear in the ascending aorta (aortic dissection) without open surgery. Only one patient was enrolled, and the study was terminated early. The main goal was to see if patients survived 30 days after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Medtronic Valiant PS-IDE Stent Graft System
- What this could lead to
- If successful, this approach could offer a less invasive treatment option for ascending aortic dissection, potentially reducing recovery time and surgical risks.
- What could go wrong
- This was a very early feasibility study with only 1 participant and was terminated early, so results are extremely limited. The procedure carries risks such as bleeding, stroke, or device failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1 person
The number who actually took part.
- Started
-
Dec 2018
- Finished
-
Oct 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * In order to qualify for this physician-sponsored Investigational Device Exemption, the patients would have to meet the entire entry criteria listed below, sign a consent approved by the FDA and IRB, and agrees to follow-up according to the study protocol. * Patient must have a type A thoracic aortic dissection, retrograde type A thoracic aortic dissection of the ascending thoracic aorta affecting the area between the Sinus of Valsalva and the innominate artery orifice (with no involvement of the aortic valve) and be considered a candidate for endovascular repair; * The proximal and distal landing zones for placement of graft should be at least 1 cm. * The proximal landing zone will allow placement of the stent graft as to not inhibit valvular function, occlude a coronary ostium or proximal bypass graft; The aortic root may be dissected, but the proximal tear site must be at least 1cm from the STJ (and within the above listed size criteria). * Distal landing zone must allow for continued perfusion of critical cerebral vessels; * The aorta as measured adventitial wall to adventitial wall must be greater than 28 mm and no more than 44 mm maximum diameter at both the proximal and distal landing zone. * The patient must be high-risk surgical candidate according to the following established criteria: ASA score of IV. Exclusion Criteria: * Pregnant or pediatric patients (younger than 21 years of age); * Patients who have a condition that threatens to infect the stent graft/aortic valve prosthesis; * Patients with allergies to the stent graft material; * Patients or their legally authorized representative (LAR) who do not sign the informed consent; * Patients with expected survival less than one year due to a condition other than the ascending aortic
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dissection of thoracic aorta are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor Scott & White The Heart Hospital
Plano, Texas, 75035, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.